1)河上 裕(編) : がん免疫療法─腫瘍免疫学の最新知見から治療法のアップデートまで.実験医学(増刊号),2016
2)Hanahan D, et al : Hallmarks of Cancer : The Next Generation. Cell 144 : 646, 2011
3)Chen DS, et al : Oncology meets immunology : the cancer-immunity cycle. Immunity 39 : 1─10, 2013
4)Chen DS, et al : Elements of cancer immunity and the cancer-immune set point. Nature 541 : 321─330, 2017
5)Kawakami Y, et al : Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95 : 784─791, 2004
6)Kawakami Y, et al : Improvement of cancer immunotherapy by combining molecular targeted therapy. Front Oncol 3 : 136, 2013
7)Yaguchi T, et al : Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28 : 393─399, 2016
8)Ishikawa T, et al : Tumor-specific Immunological Recognition of Frameshift-mutated Peptides in Colon Cancer with Microsatellite Instability. Cancer Res 63 : 5564─5572, 2003
9)Sumimoto H, et al : The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med 203 : 1651─1656, 2006
10)Kudo-Saito C, et al : Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell 16 : 195─206, 2009
11)Yaguchi T, et al : Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol 189 : 2110─2117, 2012
12)Nishio H, et al : Immunosuppression through constitutively activated NF-κB signaling in human ovarian cancer and its reversal by a NF-κB inhibitor. Bri J Cancer 110 : 2965─2974, 2014
13)Kinoshita T, et al : Determination of poor prognostic immune features of tumor microenvironment in nonsmoking patients with lung adenocarcinoma. Eur J Cancer 86 : 15─27, 2017
14)Nakamura K, et al : Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci 109 : 54─64, 2018
15)Pagés F, et al : International consortium-based validation of Immunoscore for the classification of colon cancer, Lancet in press